Dominic Piscitelli
About Dominic Piscitelli
Dominic Piscitelli is the Chief Financial Officer with extensive experience in finance, having played significant roles in major acquisitions and IPOs.
Current Title and Roles
Dominic Piscitelli currently holds the position of Chief Financial Officer. He also serves on the board of directors for Celyad Oncology and Alterome, where he is the audit committee chair for both organizations.
Educational Background
Dominic Piscitelli obtained a bachelor's degree in accounting and an MBA from Hofstra University. Additionally, he is a certified public accountant, highlighting his extensive expertise in financial management and accounting.
Professional Background and Career Path
Dominic Piscitelli began his career with KPMG, followed by various impactful roles at OSI Pharmaceuticals, where he culminated as Vice President, Treasury & Management Finance and significantly contributed to their acquisition by Astellas. He further held the Vice President of Finance, Strategy and Investor Relations position at Medivation, playing a key role in their acquisition by Pfizer. Later, as CFO of AnaptysBio, he helped raise over $500 million through IPO and follow-on financings.
Significant Financial Achievements
Dominic Piscitelli has been instrumental in significant financial milestones throughout his career. At AnaptysBio, he successfully raised over $500 million in an IPO and follow-on financings. During his tenure at Medivation, he played a crucial role in their acquisition by Pfizer. His contributions at OSI Pharmaceuticals were pivotal in their acquisition by Astellas.
Board Memberships and Audit Leadership
In addition to his executive roles, Dominic Piscitelli serves on the boards of Celyad Oncology and Alterome and is the audit committee chair for both organizations. His leadership in audit committees underscores his expertise in financial oversight and governance.